Summary This study examined the autocrine production of TGF-,B1, -,B2 and -,B3 in culture supernatants from tumour-derived (H series, n =7; BICR series, n = 5), Ha-ras-transfected (n = 4) and normal (n =2) human keratinocytes using a sandwich enzyme-linked immunosorbent assay (ELISA). Detection limits were 39.0 pg ml-1' for TGF-,ll, 78.0 pg ml-' for TGF-fl2 and 1.9 ng ml-' for TGF-,B3. Tumour-derived oral keratinocytes predominantly produced less TGF-,B1 than normal oral epithelial cells; the expression of endogenous TGF-,B2 was variable. In keratinocytes containing mutant Ha-ras, TGF-,B1 production was enhanced and TGF-#2 was undetectable. TGF-,B3 mRNA was detected by reverse transcription -polymerase chain reaction (RT-PCR) but the protein was not detected in conditioned media, most probably because of the low detection limits of the ELISA for this isoform. Neutralisation experiments indicated that the latent TGF-,B peptide was secreted in keratinocyte conditioned medium. Seven tumour-derived keratinocyte cell lines (H series) and fibroblasts separated from normal (n = 1) and tumour-derived (n =2) keratinocyte cultures were examined for their response to exogenous TGF-fil, -fl2 and -fl3. Six of seven tumour-derived keratinocyte cell lines were inhibited by TGF-,B1 and TGF-,B2 (-,IB > -,2); one cell line was refractory to both TGF-fll and TGF-,B2. Keratinocytes were inhibited (4 of 7), stimulated (1 of 7) or failed to respond (2 of 7) to TGF-,B3. TGF-,Bl, -fl2 and -,B3 stimulated both normal and tumour-associated fibroblasts, but the tumour-associated fibroblasts showed less response to the ligands than their normal counterparts following prolonged treatment with each isoform. The results demonstrate variable autocrine production of TGF-,B isoforms by malignant keratinocytes, with loss of TGF-,lB generally associated with the tumour-derived phenotype and modification of endogenous isoform production dependent on the genetic background of the tumour cells. Further, the variable response of the tumour-derived keratinocytes and contiguous fibroblasts to the TGF-,B isoforms suggests that dysregulation of TGF-,B autocrine and paracrine networks are common characteristics of squamous epithelial malignancy.
The human TGF-fl family of growth factors (TGF-fB1, -fl2 and -fl3) are highly conserved, ubiquitous peptides that exhibit a remarkable diversity of biological action . Although members of the TGF-fl family share many functional properties, it is now recognised that the TGF-fl isoforms can be distinguished with respect to their effect on cell growth (Jennings et al., 1988) , their binding to cell surface receptors (Cheifetz et al., 1990) and by the regulation of their expression with respect to other growth modulators (Danielpour et al., 1991) . Furthermore, the pattern of expression of the TGF-,B isoforms in embryogenesis (Pelton et al., 1991) and wound healing (Levine et al., 1993) is both spatially and temporally specific, which suggests defined functions for these proteins in tissue and cell behaviour.
TGF-fl binds to specific high-affinity cell surface receptors (types I, II and III) which, in epithelial cells, results in the inhibition of c-myc gene transcription and growth arrest in the late GI phase of the cell cycle (Coffey et al., 1988; Pietenpol et al., 1990; Munger et al., 1992) . It has been reported that many cell lines are either refractory or partially responsive to TGF-f11 (Fynan and Reiss, 1993) and this, in turn, has led to the concept that loss of TGF-fl responsiveness is a critical step in epithelial tumour development resulting in unrestrained tumour growth. The vast majority of studies have examined TGF-,B1 only without reference to TGF-fl2 or TGF-f,3 and, therefore, the possibility exists that tumour cells lose response to one isoform but are growth inhibited/stimulated by others. We (Prime et al., 1994) and others (B Ozanne, personal communication) have shown that human tumour-derived oral keratinocytes are inhibited by TGF-fll to varying degrees, but their response to TGF-,B2 and -#3 is currently unknown.
Almost all cell types express one or more of the TGF-,B mRNAs (Derynck et al., 1987) and the protein is usually secreted in the latent, inactive form. The physiological mechanism(s) of activation of latent TGF-,B are unclear (Lawrence, 1995) but are critical to the function of TGF-,B in tumour development. If TGF-fB does act as an autocrine negative regulator of cell growth (Wu et al., 1992) , modulation of the synthesis of the peptide may directly influence tumour behaviour. Unfortunately, definitive evidence for the role of TGF-/ in epithelial carcinogenesis in vivo using sense and anti-sense constructs of TGF-fll cDNA has been equivocal, with data to support a positive (Arteaga et al., 1993) and negative (Wu et al., 1992) function. Similarly, there are conflicting data demonstrating either overexpression or loss of expression of one or more of the TGF-fl isoforms in murine carcinomas and papillomas with a high rate of malignant transformation (Glick et al., 1993; Cui et al., 1994; Patamalai et al., 1994) and in a variety of human carcinomas (Coombs et al., 1993; MacCallum et al., 1994; Welch et al., 1990; Gorsch et al., 1992) . Both tumour heterogeneity and the complexity of the genetic changes inherent in the neoplastic phenotype could account for these findings. The relationship between the genetic profile of tumour cells and autocrine ligand production clearly warrants further investigation. TGF-/ production and responses in keratdnocytes MS Fahey et al produce more or less autocrine TGF-fJ. In epithelial carcinogenesis, historically it has been assumed that the mesenchymal stroma is a relatively passive partner during epithelial invasion and tumour development. Recently, it has been proposed that mesenchymal tissue actively suppresses epithelial carcinogenesis and that when such active suppression is lost by tumour-associated mesenchyme, epithelial tumour development is facilitated . Unfortunately, there is a paucity of information concerning the behaviour of fibroblasts associated with epithelial malignancy and whether such cells differ from their more normal counterparts.
In this study, we have used a number of human tumourderived and ras-transfected keratinocyte cell lines whose tumorigenicity in athymic mice, together with the prevalence of ras and p53 mutations, was known. In 5% (v/v) fetal bovine serum (FBS) plus 0.6 mg mI-' L-glutamine, 0.5 pg ml-' hydrocortisone and 10 mg ml-' cholera toxin. The BICR series of cell lines and normal oral keratinocytes were grown with 3T3 fibroblast support and in the absence of cholera toxin. Contiguous fibroblasts from H357, H413 and normal oral fibroblasts were grown in DMEM with 10% (v/ v) FBS and 0.6 mg ml-' L-glutamine. The culture of the spontaneously immortalised human epidermal keratinocyte cell line (HaCaT), transfected with mutated Ha-ras (1-6, 1-7, II-3, II-4), has been described previously (Boukamp et al., 1990) . The characteristics of the keratinocyte cell lines are summarised in Table I. Preparation of conditioned medium Cells were cultured in 75 cm2 tissue culture flasks until 60-70% confluent, washed in phosphate-buffered saline (PBS) (x 3) and incubated for a further 48 h in a humidified atmosphere of 95% air/5% carbon dioxide at 37°C with 10 ml serum-free DMEM. Conditioned media (CM) was pooled, centrifuged (3000g for 10 min) and 2 pg ml-' aprotinin, leupeptin, pepstatin A, 120 pg ml-' phenylmethylsulphonyl fluoride (PMSF), 100 pg ml-' bovine serum albumin (BSA) Staining controls included omission of one or more of either the capturing antibody, the ligand, the detecting antibody or the streptavidin. The specificity of the detecting antibodies was examined by incubating 500 pg standard ligand with the corresponding non-specific antibody (e.g. TGF-,Bl with anti-TGF-/2 or anti-TGF-/3).
RNA extraction and RT-PCR Cells were grown in DMEM plus 10% (v/v) FBS until approximately 60-70% confluent, trypsinised and total RNA extracted using RNeasy total RNA columns (Qiagen). cDNA was synthesised from 1 ig total RNA using the Superscript preamplification system (Gibco-BRL) with oligo (dT) as a primer. The RNA-cDNA hybrid was denatured and a fragment of the TGF-,B3 gene was amplified using the following primers: left primer 5'-AGATCTGGGGCGCCTCA-3', and right primer, 5'-TGTCGCACGTGGGGTCT-3' (deduced from the published sequence; ten Dijke et al., 1990) from H357 was collected as described above, filter sterilised and acidified by adding 1 M hydrochloric acid for 30 min until pH 2, followed by reneutralisation in 1 M sodium hydroxide until pH 7.2. After acidification and reneutralisation, the activated CM (2 ml per well) was added to FBS (final serum concentration 1 %) and this medium ( + / -30 Mg ml-' pan anti-TGF-,ll, -,B2, -/33 antibody preincubated for 1 h at 37°C) was incubated with H400; tritiated thymidine counts were measured after 24 h. All assays were carried out on 3-6 separate occasions.
Results

ELISA for TGF-/3 isoforms
The sensitivities of the sandwich ELISAs for the human TGF-/3 isoforms are shown in Figure 1 . The detection limits were 39.0 pg ml-l for TGF-/31, 78.0 pg ml-' for TGF-f2 and 1.9 ng ml-' for TGF-/33, the latter probably reflecting the lower affinity of the anti TGF-/33 antibody. Negative staining controls and cross-reactivity of TGF-,B isoform-specific antibodies was consistently less than 3.5%.
Autocrine production of TGF-/3 isoforms The production of TGF-,B1 and TGF-/32 by the normal oral keratinocytes, the tumour-derived cell lines and the Ha-ras- The inhibitory effect of neutralising autocrine TGF-# activity on keratinocyte growth in vitro is shown in Figure 4 . H400 was markedly inhibited by the addition of 1 ng ml-' exogenous TGF-#l (A vs B) and CM from H357 (A vs F). 
Discussion
This study examined the autocrine production of TGF-1 isoforms in keratinocyte cell lines derived from a broad spectrum of human oral squamous cell carcinomas and in Ha-ras-transfected clones of the spontaneously immortalised epidermal HaCaT cell line. The sandwich ELISA used in the present study facilitated the separate measurement of TGFp1, -,B2 and -,B3 in the same culture supernatant and, thereby, extended previous work by our group in which an assay of competitive inhibition of ligand binding was used to quantify total TGF-,B autocrine production (Game et al., 1992; Prime et al., 1994) . The sensitivity and specificity of the sandwich ELISA in this study compared favourably with that described previously for TGF-,il (Danielpour, 1993) .
Several tumour types are known to secrete active TGF-,B (Arteaga et al., 1990; Takiuchi et al., 1992) . The results of the present study indicate that TGF-,B was secreted predominantly as the latent peptide. For example, the addition of a pan TGF-,B antibody to unactivated CM had no effect on thymidine incorporation in a target cell line (Figure 4 , F vs G) and acidification and reneutralisation of CM was necessary for a marked decrease in thymidine incorporation (Figure 4, D vs F) . Untreated CM also inhibited thymidine incorporation (Figure 4 , A vs F), but whether this was indicative of media depletion and/or the presence of other inhibitory factors is currently unknown. The low level of thymidine incorporation in these studies may have been due to the relatively weak effects of autocrine TGF-,B on cellular proliferation or to the loss of neutralising antibody activity during the course of the experiment. While the tumour cells in the present study appeared not to activate endogenous latent TGF-# in vitro, it seems likely that the latent peptide would be activated in vivo in view of the likely presence of plasmin, the effect of cell-cell interactions and the acidic microenvironment of the tumour milieu (Lawrence, 1995).
Autocrine-negative regulation of human breast and colon carcinoma cells by TGF-,lB has been reported previously (Arteaga et al., 1990; Hafez et al., 1990) . The expression of TGF-,B1 by the tumour-derived human oral keratinocytes in this study was variable and may reflect a normal variation about a mean. However, 10 of 12 tumourderived oral keratinocyte cell lines (exceptions H103 and H357) produced less TGF-,B1 than normal oral keratinocytes and these findings were evident using two series of cell lines established in different laboratories (H and BICR series). It is unclear as to why H103 produced high levels of TGF-#1 protein but H357 contained a genetic anomaly that could have contributed to the high protein production (discussed below). The expression of TGF-f2 was even more variable than TGF-f1. Six of twelve tumour-derived cell lines (H and BICR series) produced less TGF-,B2 than normal oral keratinocytes and only in four cell lines was the value increased. There have been a number of reports of both increased (Gorsch et al., 1992) and reduced (Coombs et al., 1993) TGF-# expression in epithelial neoplasia and such conflicting data most probably reflect the cellular origin of the tumour. In skin, loss of TGF-,B1 and/or TGF-,B2 has been demonstrated immunocytochemically in squamous cell carcinomas and in murine papillomas with a high rate of malignant conversion (Glick et al., 1994; Cui et al., 1994) .
Whether the loss of TGF-/31/-#2 has functional significance for epithelial tumour development in vivo, however, remains unclear. Anti-sense constructs of TGF-,B1 cDNA promote tumorigenic conversion of human colon carcinoma cells (Wu et al., 1992) and targeted deletion of the TGF-,B1 gene in vivo leads to progression of initiated murine keratinocytes to squamous cell carcinomas (Glick et al., 1994) . In the present study, there was no clear relationship between TGF-,B1/-,B2 autocrine production and the tumorigenicity of the cell lines in athymic mice. Interestingly, tumorigenic cell lines (H103, H314, H357, BICR-10, BICR-31, BICR-56) tended to produce high levels of TGF-f31 relative to TGF-/2 and, conversely, non-tumorigenic cell lines (H376, H400, H413) produced the same or less TGF-,B1 relative to TGF-,B2. The significance of these observations is unknown and it is cautionary to note that exceptions were evident (H 157, .
The autocrine production of the TGF-,B isoforms was examined in the context of the genetic background of the cell lines. Cells that overexpressed mutant Ha-ras (1-7, 11-3, II-4; Boukamp et al., 1990 ) produced more than twice the amount of TGF-,B1 and an absence of TGF-#2 compared with the HaCaT cell line of origin. In 1-6 cells, where mutant Ha-ras was present but not overexpressed (Boukamp et al., 1990 ), | -r r r r -x r r r r r _ F r o r r r _ F r r r r r r r -F F F F R r F F F r _ _ F A vIrl7m FM TGF-,B production and responses in keratinocytes MS Fahey et al ! 1079 TGF-,B1 production was increased and TGF-,B2 was decreased relative to HaCaT cells. These findings are consistent with the expression of TGF-fJ1 mRNA in Haras-transfected clones of HaCaT cells, but contrast with our previous data where loss of TGF-/ protein was noted by 11-3 and 11-4 cells (Game et al., 1992) . In the present study, however, we measured immunogenic TGF-,B isoforms rather than total TGF-,B concentrated by ultrafiltration (Game et al., 1992) . The data obtained for the Ha-ras-transfected HaCaT clones in the present study were supported by the findings in the only tumour-derived cell line containing mutant Ha-ras where TGF-#1 was markedly enhanced and TGF-fl2 undetectable in H357; the level of Ha-ras expression in this cell line is currently unknown. Transcriptional activation of the TGF-,B1 gene by the Ha-ras oncogene has been demonstrated previously (Geiser et al., 1991) but the present report is the first to suggest down-regulation of TGFf2 expression by mutant Ha-ras.
In the present study, the majority of the H series of tumour-derived cell lines were inhibited by TGF-fi1, TGF-f,2 and TGF-#3. In general, cells that responded to TGF-,B1 were also inhibited by TGF-f,2, albeit to a lesser extent. The cellular response to TGF-#3 was variable with evidence of inhibition (H357, H376, H400, H413), stimulation (H517) or a lack of response (H103, H314). While such variability may reflect the pattern of expression of cell surface receptors by individual cell lines and/or the cell culture conditions, the results show that a loss of response to one isoform, for example in H314, is invariably associated with a loss of response to the other isoforms of TGF-f. The data also argue against the generally held concept that loss of TGF-f, responsiveness is a ubiquitous feature of malignant epithelial cell lines (Fynan and Reiss, 1993) .
In general, TGF-f is growth stimulatory for a variety of mesenchymal cells including fibroblasts, chondrocytes and osteoblasts . In the present study, fibroblasts from normal oral mucosa were stimulated by TGF-f,l, -f2 and -#3, an effect that was more marked after 48 h than 24 h of ligand treatment. By contrast, fibroblasts derived from early cultures of tumour-derived keratinocytes (H357 and H413) lost their stimulatory response to exogenous TGF-,Bl, -#2 and -fl3 such that the cells were less responsive after 48 h compared with 24 h of ligand treatment. Schor et al. (1994) have shown that fibroblasts associated with tumour-derived keratinocytes are functionally abnormal, data that support our findings. Interestingly, tumorigenicity of ras-transfected primary murine keratinocytes can be suppressed by the addition of normal dermal fibroblasts (Dotto et al., 1988) , an effect thought to be mediated by TGF-,B3 (Missero et al., 1991) . It may be, therefore, that aberrant fibroblasts associated with epithelial tumour development provide a selective growth advantage for tumour cells in vivo by failing to produce normal levels of TGF-f3. It was not possible to test this hypothesis because of difficulties in the collection of CM from fibroblasts (loss of cell adhesion and viability occurred in serum-free media) and the lack of sensitivity of the TGF-f3 ELISA. Alternative methods of quantifying TGF-fl3 expression, such as RT-PCR, were also explored but were not without difficulty. RT-PCR is at best semi-quantitative and Colletta et al. (1990) have shown that TGF-,B regulation occurs posttranscriptionally suggesting that protein production should be measured directly rather than by mRNA alone. Nevertheless, we demonstrate TGF-#3 autocrine production by both normal and tumour-derived fibroblast cell lines using RT-PCR. The study of mesenchymal control of epithelial tumour development via TGF-# warrants further investigation in view of the recent work of Shah et al. (1995) demonstrating isoform-specific effects of TGF-,B in wound healing.
In conclusion, this study demonstrates variable autocrine production of TGF-fI and -#2 by human tumour-derived 
